Shunchang Jiao

机构：Chinese PLA General Hospital · ORCID：0000-0002-9120-5233

发表论文 63 篇 · 总被引 1209 次 · h-index 18

代表论文

• Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial (2023 · EBioMedicine · 被引 53)
• Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial (2025 · The Lancet Oncology · 被引 47)
• Methylation of NRN1 is a novel synthetic lethal marker of PI3K‐Akt‐mTOR and ATR inhibitors in esophageal cancer (2021 · Cancer Science · 被引 34)
• TP53 R273C Mutation Is Associated With Poor Prognosis in LGG Patients (2022 · Frontiers in Genetics · 被引 30)
• A nomogram‑based immunoprofile predicts clinical outcomes for stage II and III human colorectal cancer (2021 · Molecular and Clinical Oncology · 被引 23)
• Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers (2021 · Frontiers in Immunology · 被引 20)